Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

January 31, 2014

Study Completion Date

July 31, 2014

Conditions
Esophageal NeoplasmsStomach NeoplasmsNeoplasm Metastasis
Interventions
DRUG

capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)

"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."

Trial Locations (2)

27710

Duke University Medical Center, Durham

27157-0001

University of Wake Forest Baptist Medical Center, Winston-Salem

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Sanofi

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Duke University

OTHER